Cosmetic safety: vaginal suppositories.
- Extends the sale of boric acid vaginal suppositories until 2035 unless regulated by the FDA.
- Requires warning labels on boric acid vaginal suppositories starting January 2027 about pregnancy risks.
- Exempts these products from prohibition if they become FDA-regulated drugs.
- Takes effect immediately to ensure continued access to necessary women's health products.
Senator Weber Pierson's legislation extends California's timeline for allowing boric acid in vaginal suppositories while implementing new safety requirements. The bill delays the state's planned 2027 prohibition on boric acid-containing vaginal suppositories until 2035, provided they are not regulated as drugs by the FDA before then.
Beginning January 2027, manufacturers must include detailed warning labels on vaginal suppositories containing boric acid. These labels must advise consumers to consult healthcare providers before use, particularly for those with certain medical conditions. The warnings must also specify that the products should not be used during pregnancy or while trying to conceive, and include instructions to discontinue use if irritation or other adverse effects occur.
The bill's findings cite research from Johns Hopkins University indicating that intravaginal boric acid represents one of few available treatments for recurring vaginal infections, including drug-resistant cases. While studies suggest the treatment is generally well-tolerated, the findings note limited data on safety during pregnancy, with animal studies showing potential risks from high oral exposure. The legislation maintains the existing exemption for trace amounts of prohibited ingredients that are technically unavoidable during manufacturing.
 Akilah Weber PiersonD Senator | Bill Author |  Not Contacted |
Email the authors or create an email template to send to all relevant legislators.
Introduced By
Latest Voting History
| Ayes | Noes | NVR | Total | Result |
|---|---|---|---|---|
| 75 | 0 | 4 | 79 | PASS |
- Extends the sale of boric acid vaginal suppositories until 2035 unless regulated by the FDA.
- Requires warning labels on boric acid vaginal suppositories starting January 2027 about pregnancy risks.
- Exempts these products from prohibition if they become FDA-regulated drugs.
- Takes effect immediately to ensure continued access to necessary women's health products.
Email the authors or create an email template to send to all relevant legislators.
Introduced By
Senator Weber Pierson's legislation extends California's timeline for allowing boric acid in vaginal suppositories while implementing new safety requirements. The bill delays the state's planned 2027 prohibition on boric acid-containing vaginal suppositories until 2035, provided they are not regulated as drugs by the FDA before then.
Beginning January 2027, manufacturers must include detailed warning labels on vaginal suppositories containing boric acid. These labels must advise consumers to consult healthcare providers before use, particularly for those with certain medical conditions. The warnings must also specify that the products should not be used during pregnancy or while trying to conceive, and include instructions to discontinue use if irritation or other adverse effects occur.
The bill's findings cite research from Johns Hopkins University indicating that intravaginal boric acid represents one of few available treatments for recurring vaginal infections, including drug-resistant cases. While studies suggest the treatment is generally well-tolerated, the findings note limited data on safety during pregnancy, with animal studies showing potential risks from high oral exposure. The legislation maintains the existing exemption for trace amounts of prohibited ingredients that are technically unavoidable during manufacturing.
Latest Voting History
| Ayes | Noes | NVR | Total | Result |
|---|---|---|---|---|
| 75 | 0 | 4 | 79 | PASS |
Akilah Weber PiersonD Senator | Bill Author | Not Contacted |